LOVFF
Cannara Biotech Inc.
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Last price
1.46
▲ 0.03 (2.03%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.46
Prev close
1.43
Day high
1.43
Day low
1.43
Volume
100
Market cap
$144.22M
P/E (TTM)
18.25
52W range
1.11 – 1.47
Trailing performance
Returnvs SPY
1W
+2.10%
+3.5%
1M
+8.15%
+4.4%
3M
+15.87%
+12.8%
6M
+9.77%
-1.3%
YTD
+14.96%
+2.7%
1Y
+8.96%
-11.0%
3Y
+82.57%
+8.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on LOVFF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
49.49M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 2, 26 | Sosiak (Nicholas) Senior Officer of Issuer |
BUY | 16.80K | $20.63K | Direct |
| Feb 11, 26 | Krivorot (Zohar) Director of Issuer |
SELL | 333.33K | $515.67K | Direct |
| Jan 27, 26 | Olds (Donald John) Director of Issuer |
— | 12.00K | — | Direct |
| Jan 27, 26 | Olds (Donald John) Director of Issuer |
— | 12.00K | — | Indirect |
| Jan 19, 26 | Olds (Donald John) Director of Issuer |
— | 19.00K | — | Direct |
| Jan 19, 26 | Olds (Donald John) Director of Issuer |
— | 19.00K | — | Indirect |
| Jan 2, 26 | Sosiak (Nicholas) Senior Officer of Issuer |
COMPENSATION | 312.50K | $398.44K | Direct |
| Jan 1, 26 | Krivorot (Zohar) Director of Issuer |
— | 468.75K | — | Direct |
| Dec 8, 25 | Fox (Mary) Director of Issuer |
— | 15.00K | — | Direct |
| Dec 8, 25 | Kay (Jack M.) Director of Issuer |
— | 15.00K | — | Direct |
| Dec 8, 25 | Olds (Donald John) Director of Issuer |
— | 35.00K | — | Direct |
| Dec 8, 25 | Stern (Derek Elan) Director of Issuer |
— | 25.00K | — | Direct |
| Oct 7, 25 | Stern (Derek Elan) Director of Issuer |
CONVERSION | 3.46M | $4.47M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Fox (Mary) |
Director of Issuer | 15.00K | Exercise of rights |
Kay (Jack M.) |
Director of Issuer | 234.00K | Exercise of rights |
Krivorot (Zohar) |
Director of Issuer | 926.89K | Acquisition or disposition under a prospectus exemption |
Olds (Donald John) |
Director of Issuer | 4.00K | Change in nature of ownership |
Sosiak (Nicholas) |
Senior Officer of Issuer | 821.72K | Acquisition or disposition in the public market |
Stern (Derek Elan) |
Director of Issuer | 401.04K | Exercise of rights |
Fundamentals
Market cap$144.22M
Enterprise value$159.41M
Revenue (TTM)$117.33M
Gross profit$49.97M
EBITDA$24.73M
Net income$10.86M
EPS (TTM)$0.08
Free cash flow$3.19M
Total cash$21.81M
Total debt$37.00M
Book value / share$0.92
Shares outstanding98.78M
Float45.25M
Short % of float—
Dividend yield—
Beta (5Y)0.35
Valuation & profitability ratios
Trailing P/E18.25
Forward P/E—
PEG ratio—
Price / sales—
Price / book1.58
EV / revenue1.36
EV / EBITDA6.45
Gross margin42.59%
Operating margin23.12%
Profit margin9.25%
Return on equity9.68%
Return on assets6.26%
Debt / equity29.40
Current ratio3.00
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $107.20M | $81.75M | $57.26M | $35.84M | +31.1% |
| Operating revenue | $152.47M | $114.25M | $76.19M | $43.97M | +33.5% |
| Cost of revenue | $60.10M | $51.96M | $30.03M | $18.51M | +15.7% |
| Gross profit | $47.10M | $29.79M | $27.23M | $17.33M | +58.1% |
| Research & development | $711.23K | $1.12M | $1.03M | $1.26M | -36.6% |
| Selling, general & admin | $23.17M | $19.65M | $13.52M | $10.03M | +17.9% |
| Total operating expense | $25.33M | $21.74M | $15.21M | $12.36M | +16.5% |
| Operating income | $21.77M | $8.04M | $12.02M | $4.98M | +170.7% |
| Net interest income | -$4.10M | -$5.47M | -$5.01M | -$3.22M | +25.1% |
| Pre-tax income | $18.10M | $4.48M | $6.95M | $2.31M | +303.6% |
| Tax provision | $5.02M | -$1.95M | $0 | — | +356.9% |
| Net income | $13.08M | $6.44M | $6.95M | $2.31M | +103.1% |
| Net income to common | $13.08M | $6.44M | $6.95M | $2.31M | +103.1% |
| Basic EPS | 0.14 | 0.07 | 0.08 | 0.03 | +100.0% |
| Diluted EPS | 0.14 | 0.07 | 0.08 | 0.03 | +100.0% |
| EBIT | $21.86M | $9.33M | $11.48M | $5.09M | +134.3% |
| EBITDA | $28.55M | $15.68M | $16.42M | $9.02M | +82.0% |
| Basic shares | 90.87M | 90.07M | 89.30M | 87.67M | +0.9% |
| Diluted shares | 92.37M | 91.39M | 89.74M | 87.84M | +1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $14.36M | $6.62M | $4.27M | $12.11M | +116.9% |
| Cash & short-term investments | $14.36M | $6.62M | $4.27M | $12.11M | +116.9% |
| Accounts receivable | $14.11M | $13.04M | $10.59M | $8.53M | +8.2% |
| Inventory | $51.33M | $40.07M | $33.77M | $18.98M | +28.1% |
| Total current assets | $82.16M | $67.47M | $51.70M | $40.99M | +21.8% |
| Property, plant & equipment | $86.28M | $85.04M | $89.51M | $84.33M | +1.5% |
| Total assets | $168.65M | $154.72M | $141.52M | $125.62M | +9.0% |
| Total current liabilities | $34.20M | $27.00M | $21.18M | $11.86M | +26.7% |
| Current debt | $13.02M | $9.23M | $5.97M | $1.97M | +41.1% |
| Long-term debt | $28.17M | $38.45M | $39.64M | $46.19M | -26.7% |
| Total debt | $41.58M | $48.33M | $45.78M | $48.39M | -14.0% |
| Total liabilities | $66.43M | $66.77M | $61.78M | $58.88M | -0.5% |
| Retained earnings | $178.28K | -$12.90M | -$19.34M | -$26.30M | +101.4% |
| Shareholder equity | $102.22M | $87.95M | $79.74M | $66.74M | +16.2% |
| Working capital | $47.96M | $40.47M | $30.51M | $29.13M | +18.5% |
| Net tangible assets | $102.22M | $87.95M | $79.74M | $66.74M | +16.2% |
| Shares issued | 91.43M | 90.02M | 90.31M | 87.70M | +1.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $13.08M | $6.44M | $6.95M | $2.31M | +103.1% |
| Depreciation & amortisation | $6.68M | $6.35M | $4.94M | $3.92M | +5.2% |
| Stock-based compensation | $1.19M | $1.98M | $1.75M | $349.47K | -39.6% |
| Change in working capital | -$6.30M | -$2.50M | -$5.64M | -$11.48M | -152.3% |
| Operating cash flow | $20.01M | $10.68M | $5.91M | -$6.08M | +87.3% |
| Capital expenditure | -$6.36M | -$7.47M | -$9.88M | -$15.47M | +14.9% |
| Investing cash flow | -$5.95M | -$5.19M | -$9.48M | -$15.35M | -14.7% |
| Share buybacks | $0 | -$277.14K | -$374.49K | $0 | +100.0% |
| Dividends paid | $0 | $0 | $0 | $0 | — |
| Financing cash flow | -$6.32M | -$3.14M | -$4.19M | $25.46M | -101.1% |
| Free cash flow | $13.65M | $3.21M | -$3.97M | -$21.55M | +324.9% |
| End cash position | $14.36M | $6.62M | $4.27M | $12.11M | +116.9% |
| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $31.83M | $27.18M | $30.11M | $28.21M | $27.33M | — | +17.1% |
| Operating revenue | $45.07M | $37.82M | $42.80M | $40.09M | $38.80M | — | +19.2% |
| Cost of revenue | $16.80M | $15.53M | $18.90M | $16.13M | $14.45M | — | +8.1% |
| Gross profit | $15.03M | $11.65M | $11.21M | $12.09M | $12.88M | — | +29.1% |
| Research & development | $344.71K | $400.69K | $287.45K | $191.15K | $176.94K | — | -14.0% |
| Selling, general & admin | $7.09M | $7.59M | $7.95M | $6.33M | $5.72M | — | -6.6% |
| Total operating expense | $7.67M | $8.25M | $8.51M | $7.19M | $6.12M | — | -6.9% |
| Operating income | $7.36M | $3.40M | $2.70M | $4.90M | $6.76M | — | +116.3% |
| Net interest income | -$464.31K | -$507.86K | -$598.95K | -$787.22K | -$1.00M | — | +8.6% |
| Pre-tax income | $6.87M | $2.82M | $2.04M | $4.54M | $5.79M | — | +143.7% |
| Tax provision | $2.03M | $1.16M | $1.00M | $1.23M | $1.65M | — | +75.4% |
| Net income | $4.84M | $1.66M | $1.04M | $3.31M | $4.14M | — | +191.3% |
| Net income to common | $4.84M | $1.66M | $1.04M | $3.31M | $4.14M | — | +191.3% |
| Basic EPS | 0.05 | 0.02 | 0.01 | — | 0.05 | 0.04 | +150.0% |
| Diluted EPS | 0.05 | 0.02 | 0.01 | — | 0.04 | 0.04 | +150.0% |
| EBIT | $7.37M | $3.32M | $2.65M | $5.35M | $6.73M | — | +122.0% |
| EBITDA | $8.99M | $4.63M | $4.23M | $7.58M | $7.99M | — | +94.4% |
| Basic shares | 98.78M | 96.36M | 93.72M | — | 91.43M | 90.56M | +2.5% |
| Diluted shares | 100.52M | 98.42M | 96.18M | — | 92.61M | 92.25M | +2.1% |
| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.81M | $21.90M | $16.52M | $14.36M | $14.41M | -0.4% |
| Cash & short-term investments | $21.81M | $21.90M | $16.52M | $14.36M | $14.41M | -0.4% |
| Accounts receivable | $18.52M | $12.47M | $15.22M | $14.11M | $14.09M | +48.5% |
| Inventory | $55.63M | $54.15M | $51.97M | $51.33M | $48.99M | +2.7% |
| Total current assets | $97.69M | $91.13M | $85.04M | $82.16M | $84.00M | +7.2% |
| Property, plant & equipment | $93.95M | $90.36M | $88.52M | $86.28M | $85.95M | +4.0% |
| Goodwill & intangibles | $2.68M | — | — | — | — | — |
| Total assets | $194.49M | $181.81M | $173.84M | $168.65M | $170.09M | +7.0% |
| Total current liabilities | $32.57M | $29.79M | $31.50M | $34.20M | $34.62M | +9.4% |
| Current debt | $9.62M | $8.78M | $8.86M | $13.02M | $13.04M | +9.5% |
| Long-term debt | $27.20M | $25.20M | $25.62M | $28.17M | $33.97M | +8.0% |
| Total debt | $37.00M | $34.22M | $34.80M | $41.58M | $47.47M | +8.1% |
| Total liabilities | $68.64M | $61.60M | $62.63M | $66.43M | $71.49M | +11.4% |
| Retained earnings | $7.72M | $2.88M | $1.22M | $178.28K | -$3.14M | +168.1% |
| Shareholder equity | $125.85M | $120.21M | $111.21M | $102.22M | $98.59M | +4.7% |
| Working capital | $65.12M | $61.34M | $53.54M | $47.96M | $49.39M | +6.1% |
| Net tangible assets | $123.16M | $120.21M | $111.21M | $102.22M | $98.59M | +2.5% |
| Shares issued | 98.78M | 98.78M | 94.90M | 91.43M | 91.43M | 0.0% |
| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $4.84M | $1.66M | $1.04M | $3.31M | $4.14M | — | +191.3% |
| Depreciation & amortisation | $1.63M | $1.31M | $1.58M | $2.23M | $1.26M | — | +24.4% |
| Stock-based compensation | $794.07K | $1.09M | $1.72M | $313.95K | $262.77K | — | -27.2% |
| Change in working capital | -$2.37M | -$2.70M | -$163.33K | -$4.15M | $6.53M | — | +12.1% |
| Operating cash flow | $5.68M | $2.95M | $7.96M | $2.83M | $13.90M | — | +92.7% |
| Capital expenditure | -$4.40M | -$3.23M | -$4.62M | -$1.47M | -$2.21M | — | -36.2% |
| Investing cash flow | -$7.04M | -$3.01M | -$4.56M | -$1.24M | -$2.14M | — | -134.2% |
| Share buybacks | — | — | — | $0 | $0 | $0 | — |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | — | — |
| Financing cash flow | $1.26M | $5.44M | -$1.25M | -$1.63M | -$2.41M | — | -76.8% |
| Free cash flow | $1.28M | -$286.30K | $3.34M | $1.36M | $11.70M | — | +545.9% |
| End cash position | $21.81M | $21.90M | $16.52M | $14.36M | $14.41M | — | -0.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $34.40M | — |
| Next quarter | — | — | $35.30M | — |
| Current year | — | — | $123.32M | +14.9% |
| Next year | — | — | $145.97M | +18.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders50.10%
Held by institutions0.25%
Institutions holding1
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.43
+2.13% from price
SMA 20
1.40
+4.26% from price
SMA 50
1.31
+11.50% from price
SMA 100
1.29
+12.84% from price
SMA 200
1.29
+13.04% from price
EMA 12
1.42
+2.82% from price
EMA 26
1.39
+5.41% from price
EMA 50
1.34
+8.61% from price
RSI (14)
63.8
Neutral
MACD (12,26,9)
0.03
Hist -0.00
ATR (14)
0.03
1.83% of price
Realised vol 30D
41.3%
Annualised
Bollinger upper
1.47
20, 2σ
Bollinger lower
1.33
20, 2σ
50 / 200 cross
Golden
1.31 vs 1.29
Trend bias
Above 200
+13.04%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.11
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
41.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-22.6%
Peak to trough
Max drawdown 5Y
-70.9%
Peak to trough
ATR 14
0.03
1.83% of price
Beta (reported)
0.35
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateFeb 13, 2023
Headlines
Cannara Establishes Automatic Share Purchase Plan
GlobeNewswire · 10d ago
Cannara Biotech to Begin a Normal Course Issuer Bid
MT Newswires · 32d ago
Cannara Announces Normal Course Issuer Bid
GlobeNewswire · 32d ago
Cannara Biotech Price Target Raised to C$4 at TD
MT Newswires · 38d ago
Cannara Biotech Inc (LOVFF) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
GuruFocus.com · 38d ago
Cannara Biotech Fiscal Q3 Earnings, Revenue Rise
MT Newswires · 39d ago
Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
GlobeNewswire · 39d ago
Cannara Biotech Strikes Long-Term Supply Agreement With Curaleaf
MT Newswires · 39d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.